The diabetes management technologies market is expected to grow by 2034, driven by advancements in glucose monitoring, insulin delivery, and digital health solutions. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Diabetes Management Technologies Market
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. North America
8.1.1. Market Revenue and Forecast
8.1.2. U.S.
8.1.2.1. Market Revenue and Forecast
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast
8.2. Europe
8.2.1. Market Revenue and Forecast
8.2.2. UK
8.2.2.1. Market Revenue and Forecast
8.2.3. Germany
8.2.3.1. Market Revenue and Forecast
8.2.4. France
8.2.4.1. Market Revenue and Forecast
8.2.5. Rest of Europe
8.2.5.1. Market Revenue and Forecast
8.3. APAC
8.3.1. Market Revenue and Forecast
8.3.2. India
8.3.2.1. Market Revenue and Forecast
8.3.3. China
8.3.3.1. Market Revenue and Forecast
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast
8.4. MEA
8.4.1. Market Revenue and Forecast
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast
8.5. Latin America
8.5.1. Market Revenue and Forecast
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast
9.1. F. Hoffmann-La Roche Ltd.
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Tandem Diabetes Care, Inc.,
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Medtronic
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Bayer AG,
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Abbott
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Sanofi
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Dexcom, Inc.
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. LifeScan, Inc.
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. B. Braun Melsungen AG
9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
9.10. Insulet Corporation
9.10.1. Company Overview
9.10.2. Product Offerings
9.10.3. Financial Performance
9.10.4. Recent Initiatives
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
11.1. About Us
11.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample